Assessment of the safety and efficacy of a glucokinase activator (AZD1656) in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19. A randomised double-blind, placebo-controlled clinical trial. This evidence concerns the gene GCK and type 2 diabetes mellitus.